Skip to main content

Pharma News

Pharma Courses

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • UConn Researcher Develops Successful Zika Virus Vaccine in Preclinical Studies

    UConn researcher Paulo Verardi, associate professor of pathobiology and veterinary science in the College of Agriculture, Health and Natural Resources, has demonstrated the success of a vaccine against Zika virus and recently published his findings in Scientific Reports, a Nature Research publication.

  • Alor Dermaceuticals receives USFDA approval for Nystatin and Triamcinolone acetonide cream

    Alembic Pharmaceuticals Limited announced that its joint venture Aleor Dermaceuticals Limited (Aleor) has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Nystatin and Triamcinolone Acetonide Cream USP, 100,000 units/gram and 1 mg/gram. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Nystatin and Triamcinolone Acetonide Cream USP, 100,000 units/gram and 1 mg/gram, of Taro Pharmaceuticals U.S.A. Inc.

  • New hope for mitochondrial disorders

    Efforts to find a treatment for mitochondrial disorders is set to get a major boost with a team of researchers at the Department of Biotechnology’s National Institute of Immunology (DBT-NII) figuring out a way to tackle autosomal dominant progressive external ophthalmoplegia (adPEO), which is a widely prevalent mitochondrial disorder.

  • Salt substitution is effective to reduce blood pressure in rural India

    Replacing regular common salt consumed by hypertensive patients in rural areas with a salt substitute can have a significant impact in terms of lowering their blood pressure, a new study by The George Institute for Global Health (GIGH) has revealed.

  • Cold-virus saved lives from corona virus in India, says Research

    Despite rising cases of corona infection, the rate of deaths due to Covid-19 outbreaks has been lower in India than in the US and the United Kingdom. This has emerged in a new study by scientists of the National Institute of Immunology (NII) and All India Institute of Medical Sciences (AIIMS) based in New Delhi. Researchers say one of the reasons for the decrease in the rate of deaths caused by Covid-19 in India may be prior exposure to the corona responsible for the common cold.

  • High Liver Fat (Hepatic Steatosis) Linked to Increased Risk of Hospitalization in COVID-19 Patients With Obesity

    New research published this month in Frontiers in Medicine (Gastroenterology) reveals that individuals with both obesity and severe fatty liver are five times more likely to require hospitalization for the illness. The non-invasive liver imaging technology — Perspectum’s LiverMultiScan — was used to gather MRI scans for the study.

  • Germany and Canada halted use of the AstraZeneca vaccine in elderly patients

    Germany and Canada have restricted the use of the AstraZeneca vaccine to people over 60 and 55 respectively, due to fear that it can lead to deadly blood clots.

    Health Minister of Germany, Jens Spahn and state officials agreed unanimously on Tuesday to only give the vaccine to people aged 60 or older unless they belong to a high-risk category for serious illness from COVID-19 and have agreed with their doctor to take the vaccine despite the small risk of a serious side-effect.

  • Covishield and Covaxin effective against UK, Brazilian corona variants : ICMR

    ICMR reported that Covishield and Covaxin vaccines are effective against the UK and the Brazilian variants of coronavirus, and several laboratories are involved in work against South African strain. Addressing a weekly press conference of the Union health ministry, ICMR Director-General Balram Bhargava also said of 11,064 genome samples sequenced in the country, the UK variant of the virus was detected in 807, the South African variant in 47 and the Brazilian variant was found in one.

  • Takeda Begins Regulatory Submissions for Dengue Vaccine Candidate in EU and Dengue-Endemic Countries

    Takeda announced that the European Medicines Agency (EMA) has accepted the Company’s filing packages for its dengue vaccine candidate (TAK-003) which is being investigated for the prevention of dengue due to any dengue virus serotype in individuals ages four to 60. Takeda intends to submit regulatory filings in Argentina, Brazil, Colombia, Indonesia, Malaysia, Mexico, Singapore, Sri Lanka and Thailand during 2021.

  • Weekly insulin helps patients with type 2 diabetes achieve similar blood sugar control to daily insulin

    A new once-weekly basal insulin injection demonstrated similar efficacy and safety and a lower rate of low blood sugar episodes compared with a daily basal insulin, according to a phase 2 clinical trial. The study results, which will be presented at ENDO 2021, the Endocrine Society’s annual meeting, compared an investigational drug called basal insulin Fc (BIF) with insulin degludec, a commercially available long-lasting daily insulin, in patients with type 2 diabetes.

Subscribe to Pharma News